Paul H. Gumerlock
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer-related Molecular Pathways, Ubiquitin and proteasome pathways, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics
Most-Cited Works
- Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.(2002)
- → Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study(2005)584 cited
- → Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504(2003)373 cited
- → Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells(1997)358 cited
- → Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib(2007)270 cited
- CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.(1996)
- → p53 in Prostate Cancer: Frequent Expressed Transition Mutations(1994)179 cited
- → Gefitinib Therapy in Advanced Bronchioloalveolar Carcinoma: Southwest Oncology Group Study S0126(2006)153 cited
- Activated ras alleles in human carcinoma of the prostate are rare.(1991)
- → Pharmacodynamic Separation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in Non–Small-Cell Lung Cancer(2006)129 cited